Scleredema in Multiple Myeloma, Paraproteinaemia, or Amyloidosis

Clinical Scenario

This protocol addresses scleredema presenting in the setting of an associated haematological disease — paraproteinaemia, monoclonal gammopathy, multiple myeloma, or amyloidosis. The characteristic skin finding is symmetrical, woody, non-pitting induration of the neck and upper trunk, with notable sparing of the fingers.

Haematological Context

This form of scleredema (type 2) is associated with haematological diseases including paraproteinaemia, monoclonal gammopathy, multiple myeloma, and amyloidosis. Recognition of the underlying haematological condition is central to the clinical picture in these patients.

First-Line Approach

For persistent scleredema in this setting, the evidence-based first-line intervention is a phototherapy-based approach. The specific modality, parameters, and any escalation criteria are defined in the full structured protocol.

Complete regimen and sequencing available in the full protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jdv.19937

Type 2 scleroedema is associated with haematological diseases like paraproteinaemia including monoclonal gammopathy, multiple myeloma and amyloidosis.

The recommended first-line treatment is phototherapy.

Escalation of therapy in resistant cases of scleroedema is possible through the use of phototherapy (PUVA, UVA1 and narrowband UVB) or drug treatment (Table 2).

View source ↗